Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, ...

European Valuations and Interpath Advisory Limited, acting on behalf of the liquidators of Surepharm Services Limited, is ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Under Kennedy's plan, the FDA is set to bear the brunt of the job losses, with 3,500 workers due to be shed, while the CDC is ...

Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...